SEC Tracker
Get the app

Biomerica BMRA

Biomerica Q2 FY26: revenue $1.2M, down 26%; diluted EPS −$0.45

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Biomerica reported for Q2 FY26, the quarter ended Nov 30, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$1.2M−26% from $1.6M in Q2 FY2510-Q income statement, on EDGAR
  2. Net income−$1.3MAgainst −$950K in Q2 FY2510-Q income statement, on EDGAR
  3. Diluted EPS−$0.45Against −$0.06 in Q2 FY2510-Q income statement, on EDGAR
  4. Cash and cash equivalents$2.5M+7% from $2.4M in Q2 FY2510-Q balance sheet, on EDGAR
  5. Cash from operations−$991KAgainst −$791K in Q2 FY2510-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Biomerica files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2835 and related industry codes: the same peer list as the financial tables.

  1. Protagenic Therapeutics, Inc.\new PTIX public float $7M, Sep 30, 2025
  2. Adial Pharmaceuticals ADIL public float $6M, Jun 30, 2025
  3. AIM ImmunoTech AIM public float $6M, Jun 30, 2025
  4. Vyome Holdings HIND public float $6M, Jun 30, 2025
  5. PharmaCyte Biotech PMCB public float $6M, Oct 31, 2025